Physician profile
Lawrence Mathew Ehrlich
NPI 1407854631
$10,224.44
in general payments reported to CMS, 2019-2025
41 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $2,128 · 2021: $2,598 · 2022: $1,251 · 2023: $959 · 2024: $992 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,266.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,568.58 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $771.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.62 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $529.61 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $482.65 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $470.69 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $457.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $381.42 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $355.80 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $349.32 | 2019-2025 | |
| Abbvie INC. | $322.36 | 2020-2025 | |
| Corcept Therapeutics | $311.41 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $196.60 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $116.99 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $100.89 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $100.23 | 2019-2021 | |
| Radius Health, INC. | $96.39 | 2020-2025 | Tymlos |
| Exact Sciences Corporation | $87.30 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $82.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.05 | 2021-2023 | |
| Allergan, INC. | $64.76 | 2020 | |
| Horizon Therapeutics Plc | $54.64 | 2020-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $54.36 | 2019 | |
| Esperion Therapeutics, INC. | $47.36 | 2021-2025 | Nexletol |
| Scilex Pharmaceuticals INC. | $46.66 | 2019-2020 | |
| Astellas Pharma US INC | $34.94 | 2020 | |
| Edwards Lifesciences Corporation | $33.41 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Grifols USA, LLC | $33.13 | 2019-2023 | Prolastin-C Liquid |
| Teleflex LLC | $26.10 | 2025 | Urolift |
| Vbi Vaccine (Delaware) INC. | $21.28 | 2022 | |
| Axsome Therapeutics, INC. | $21.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.28 | 2021 | |
| Daiichi Sankyo INC. | $18.28 | 2020 | |
| Sumitomo Pharma America, INC. | $18.23 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $16.73 | 2024 | Inspire |
| Halozyme INC | $15.99 | 2023 | |
| Ibsa Pharma INC. | $15.83 | 2025 | Flector, Licart, Tirosint |
| Vericel Corporation | $15.43 | 2023 | Maci |
| Medicure Pharma INC. | $13.92 | 2023 | Zypitamag |
| Clarus Therapeutics INC. | $8.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.